• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Bluesight Diversion Trends Report Reveals $38M Lost to Drug Waste

by Jasmine Pennic 07/11/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Bluesight, a provider of medication intelligence solutions, released its 2024 Diversion Trends Report, offering valuable insights for healthcare providers to improve controlled substance monitoring and patient safety.

– The report demonstrates progress in healthcare’s fight against controlled substance diversion. However, the data also highlights areas for continued improvement, particularly in waste management and medication documentation. 

The report analyzes data from January 2022 to December 2023, encompassing over 127 million controlled substance transactions across 794 hospitals and health systems in the U.S. This data reveals positive trends in diversion detection and investigation efficiency:

  • Faster Investigations: Diversion investigations are closing 37 days sooner on average, indicating improved workflows and quicker evidence gathering.
  • Reduced Discrepancies: Discrepancies in controlled substance orders, administration, waste, or returns have decreased by nearly 24% since 2022, allowing hospitals to prioritize diversion detection efforts more effectively.

Key takeaways from the report include: 

  • Waste Management: Over 16 million controlled substance packages were wasted, amounting to approximately $38M in lost cost. Additionally, Fentanyl, a powerful opioid, accounted for nearly a quarter of wasted packages.
  • Documentation Errors: Half of transaction variances resulted from incorrect documentation, highlighting the importance of accurate patient, drug, and dosage information to minimize discrepancies.
  • High-Risk Areas: The report identifies nursing (77.7%), anesthesiology (11.8%), and pharmacy (5%) as departments most frequently involved in discrepancies.
  • Top Discrepant Drugs: Fentanyl (24%), Midazolam (15%), and Hydromorphone (10%) are the medications most associated with discrepancies.

“The challenge of drug diversion is an issue for all healthcare facilities, requiring a mix of consistent monitoring supported by technology and tools to help our healthcare workers effectively do their jobs. This report is a positive reminder of the impact that new systems can have in helping to tackle this problem. However, there is still more work to be done in this area,” said Kevin MacDonald, Bluesight CEO, and co-founder. “By leveraging advanced data integration and comprehensive monitoring technology, such as ControlCheck, we are setting new standards. With our commitment to continued innovation and enhanced patient safety, we support over 850 hospitals in the critical mission to improve compliance, reduce costs and track high-risk drugs and individuals.”

Report Methodology

The report leverages data from Bluesight’s ControlCheck product, analyzing controlled substance transactions across a growing network of hospitals. The significant increase in participating hospitals (from 354 to 794) contributes to the overall rise in variances, investigations, and confirmed diversion cases.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |